Preparation method of animal leukocyte extract freeze-dried powder with antioxidant activity
By using lyophilized protective agents such as trehalose and ultrafiltration concentration technology during the lyophilization process, the problems of long preparation time and loss of biological activity are solved, and high-quality and high-oxidation resistance preparation of lyophilized powder are achieved.
Patent Information
- Application Number
- CN202411303301.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-12
AI Technical Summary
During the lyophilized process, the existing lyophilized powder has a long preparation time, high energy consumption and high oxidation risk, resulting in loss of biological activity and cannot effectively maintain the antioxidant and stability of leukocyte extracts.
Specific lyophilized protective agents such as trehalose, arginine, sucrose, mannitol and polyethylene glycol are used, combined with ultrafiltration concentration and low-temperature centrifugation technology to shorten the lyophilized time and improve the stability and antioxidant ability of lyophilized powder. .
It effectively shortens the preparation time of lyophilized powder, improves its quality and antioxidant properties, and ensures better biological activity performance in applications.
Smart Images

Figure CN118924638A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biological products, and in particular to a method for preparing animal leukocyte extract freeze-dried powder with antioxidant activity. Background Art
[0002] Leukocytes are mainly obtained from the peripheral blood of cattle and extracted through a series of means to obtain active substances. It contains a variety of cytokines and active peptides that are beneficial to the human body. These components include but are not limited to growth factors, interleukins, colony stimulating factors and interferons, which play an important regulatory role in cell-to-cell interactions, immune regulation, hematopoiesis and inflammation.
[0003] In the cosmetics industry, leukocyte extracts are widely used because of their properties of promoting cell metabolism, repairing damaged tissues, anti-inflammatory and anti-oxidant. It can activate aging cells, promote cell regeneration, improve skin immunity, reduce pigmentation, improve skin quality, etc. In addition, leukocyte extracts can also work synergistically with other ingredients in cosmetics to improve cell mitochondrial function and provide comprehensive nutrients required for cell metabolism, thereby significantly enhancing its function of activating cells. The use of leukocyte extracts in cosmetics is safe and has been included in the "Catalogue of Used Cosmetic Raw Materials (2021 Edition)", and is not a prohibited substance in the "Technical Specifications for Safety of Cosmetics (2015 Edition)". Leukocyte extracts will not cause harm to human health under normal, reasonable and foreseeable conditions of use. Continuous research and development is being carried out in this field to improve the efficacy and safety of products.
[0004] However, the freeze-dried powder on the market currently does not have a good antioxidant effect. There are various problems in the freeze-drying process, including long preparation time and high energy consumption of freeze-drying, which will increase the risk of oxidation and destroy the biological activity of its main components. Therefore, how to optimize the freeze-dried formula during the freeze-drying process, shorten the freeze-drying time, improve the antioxidant and stability of proteins and nucleic acids, make their quality uniform, and play a better role in application are the technical problems we currently need to solve. Summary of the invention
[0005] The present invention provides a method for preparing animal leukocyte extract freeze-dried powder with antioxidant activity, aiming to improve the quality of the leukocyte extract freeze-dried powder and better maintain and exert its biological activity.
[0006] To achieve the above object, the present invention provides a method for preparing a freeze-dried powder of animal leukocyte extract with antioxidant activity, which is characterized by comprising the following steps: S1: Take animal blood, add anticoagulant, then add PBS solution to dilute and mix well to obtain a primary mixed solution; S2: Add lymphocyte separation solution to the initial mixed solution, perform density gradient centrifugation to separate the layers, take the middle layer to obtain mononuclear cells, wash them, and then inoculate them in culture medium for cultivation.
[0007] S3: When the cell density in the culture medium reaches a set threshold, subculture is performed and fresh culture medium is replaced for cultivation; S4: The cultured cells are collected by centrifugation to obtain a supernatant and a precipitate, and the supernatant is treated by an ultrafiltration concentration device to obtain a solution A; the precipitate is added with a PBS solution for resuspending, and after low-temperature centrifugation, a supernatant B is obtained, and the solution A and the supernatant B are mixed to obtain a leukocyte extract; S5: adding a lyophilization protective agent to the leukocyte extract, pre-cooling after mixing evenly, sublimation drying after pre-vacuuming, and finally analytical drying to obtain the animal leukocyte extract antioxidant active lyophilized powder.
[0008] Preferably, in step S1, the selected animal blood is peripheral blood; and the anticoagulant is one of heparin or sodium citrate.
[0009] Preferably, in step S2, the monocytes are washed several times with PBS solution and then inoculated in DMEM medium for culture at a temperature of 37 degrees Celsius and a carbon dioxide concentration of 5%; wherein the DMEM medium contains 5% FBS, 150U interleukin and 5μg / ml fibronectin.
[0010] Preferably, in step S3, when the cell density reaches 80-90%, subculture is performed and new culture medium is replaced for 10 days.
[0011] Prior to this, in step S4, the supernatant is concentrated by ultrafiltration using 0.22um and 0.45um filter membranes to remove impurities to obtain solution A; the precipitate is resuspended with PBS solution, added to liquid nitrogen for repeated freezing and thawing, and centrifuged at high speed and low temperature using an ultrasonic disruptor, and then separated to obtain supernatant B.
[0012] Preferably, in the process of obtaining the supernatant B, when using an ultrasonic disruptor, the conditions adopted are ultrasonication for 1-3 seconds in an ice bath, with an interval of 5-8 seconds, for 10 minutes, and 2-3 cycles.
[0013] Preferably, in step S5, the added lyoprotectant is a mixture of one or more of trehalose, arginine, dextran, sucrose, lactose, mannitol, arginine, and D-fructose, and the added amount is 6%-15% of the mass of the leukocyte extract solution. Polyethylene glycol is also required to be added.
[0014] In the technical solution of the present invention, the present application is equipped with special ingredients and a lyophilization protectant is added, so that the preparation time can be effectively shortened during the preparation of lyophilized powder, the stability of the lyophilized powder can be well maintained, the quality of the lyophilized powder can be improved, and the foundation for industrial application is effectively laid; in addition, due to the presence of the protectant, the lyophilized powder has good antioxidant ability and can meet the use requirements. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 It is a schematic diagram of the steps of the present invention; Figure 2-Figure 4 It is a detection diagram of the implementation results of the present invention. DETAILED DESCRIPTION
[0016] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0017] It should be noted that if the embodiments of the present invention involve directional indications (such as up, down, left, right, front, back...), the directional indications are only used to explain the relative position relationship, movement status, etc. between the components under a certain specific posture (as shown in the accompanying drawings). If the specific posture changes, the directional indication will also change accordingly.
[0018] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0019] In addition, if there are descriptions involving "first", "second", etc. in the embodiments of the present invention, the descriptions of "first", "second", etc. are only used for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In addition, if the meaning of "and / or" appearing in the full text is to include three parallel schemes, taking "A and / or B" as an example, it includes scheme A, or scheme B, or a scheme that satisfies both A and B. In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the ability of ordinary technicians in this field to implement. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such a combination of technical solutions does not exist and is not within the scope of protection required by the present invention.
[0020] See also Figure 1 The present invention provides a method for preparing a freeze-dried powder of animal leukocyte extract with antioxidant activity, comprising the following steps: S1: Take animal blood, add anticoagulant, then add PBS (phosphate buffered saline) solution to dilute and mix well to obtain a primary mixed solution; S2: Add lymphocyte separation solution to the initial mixed solution, perform density gradient centrifugation to separate the layers, take the middle layer to obtain mononuclear cells, wash them, and then inoculate them in culture medium for cultivation.
[0021] S3: When the cell density in the culture medium reaches a set threshold, subculture is performed and fresh culture medium is replaced for cultivation; S4: The cultured cells are collected by centrifugation to obtain a supernatant and a precipitate, and the supernatant is treated by an ultrafiltration concentration device to obtain a solution A; the precipitate is added with a PBS solution for resuspending, and after low-temperature centrifugation, a supernatant B is obtained, and the solution A and the supernatant B are mixed to obtain a leukocyte extract; S5: adding a lyophilization protective agent to the leukocyte extract, pre-cooling after mixing evenly, sublimation drying after pre-vacuuming, and finally analytical drying to obtain the animal leukocyte extract antioxidant active lyophilized powder.
[0022] In step S1, the animal blood obtained is peripheral blood; the anticoagulant is one of heparin or sodium citrate. In the specific implementation process, bovine peripheral blood is preferably used, and the volume ratio of bovine peripheral blood, PBS solution and lymphocyte separation solution is 1:1:1.
[0023] In step S2, the monocytes are washed several times with PBS solution and then inoculated in DMEM medium for culture at a temperature of 37 degrees Celsius and a carbon dioxide concentration of 5%; wherein the DMEM medium contains 5% FBS, 150U interleukin and 5 μg / ml fibronectin.
[0024] In step S3, when the cell density reaches 80-90%, the cells are subcultured and the culture medium is replaced with new medium for 10 days.
[0025] In step S4, the supernatant is concentrated by ultrafiltration, and impurities are removed by 0.22um and 0.45um filter membranes to obtain solution A; the precipitate is resuspended with the PBS solution, added to liquid nitrogen for repeated freezing and thawing, and centrifuged at high speed and low temperature using an ultrasonic crusher, and then separated to obtain supernatant B; in the process of obtaining supernatant B, when using the ultrasonic crusher, the conditions used are ultrasonication for 1-3s under ice bath conditions, with an interval of 5-8s, for 10min, and 2-3 cycles.
[0026] In step S5, the added lyophilization protective agent is a mixture of one or more of trehalose, arginine, dextran, sucrose, lactose, mannitol, arginine, and D-fructose, and the added amount is 6%-15% of the mass of the leukocyte extract solution. Polyethylene glycol is also added.
[0027] In the specific implementation process, the lyoprotectant can be arginine, because arginine can effectively maintain the stability of proteins and prevent denaturation or aggregation during the freezing and drying process; secondly. Arginine can increase the solubility of proteins and reduce the viscosity of high-concentration protein solutions, thereby facilitating the preparation and re-dissolution of lyophilized powders; then the stability of biomacromolecules can be enhanced by adjusting the tension of the solution, which is particularly important for maintaining the stability of active ingredients in lyophilized powders; in addition, arginine has a certain pH buffering capacity, which can help maintain the stability of lyophilized powders within a specific pH range and prevent the inactivation of active ingredients caused by pH changes; finally, arginine also has antioxidant properties, which can remove free radicals in the solution and protect proteins from oxidative damage.
[0028] As for trehalose, a non-reducing disaccharide, it has a high glass transition temperature and can form a protective film on the cell surface, effectively protecting protein molecules from denaturation and inactivation, and maintaining the activity and stability of biological products. During the freeze-drying process, trehalose can prevent protein aggregation and denaturation, and improve the stability of freeze-dried powder; trehalose has good thermal stability, and can protect biological molecules and cells under high temperature conditions and reduce thermal damage. Inhibit the formation of ice crystals: During the freeze-drying process, trehalose can inhibit the growth of ice crystals, reduce cell rupture, and protect the structure of biological molecules: trehalose can regulate the osmotic pressure and crystal state of freeze-dried powder, and control the reconstitution time and quality of the preparation. Improve the physical properties of freeze-dried powder.
[0029] The present application is described below by means of specific embodiments: First, take 100ml of bovine peripheral blood, add a small amount of sodium citrate to prevent blood coagulation, then add 100ml of PBS (phosphate buffer solution) to dilute and mix, slowly add 100ml of lymphocyte separation solution, perform density gradient centrifugation stratification, take the middle layer to obtain peripheral blood mononuclear cells, then wash several times with PBS solution, inoculate in DMEM culture medium, so that the peripheral blood mononuclear cells can be expanded, and when the cell density reaches 80-90%, perform subculture treatment. After 10 days of culture, when the total amount of cells has expanded to 88-97 times, perform subsequent treatment.
[0030] The mononuclear cells are collected by centrifugation to obtain a supernatant and a precipitate, respectively. The supernatant is concentrated by ultrafiltration or dialysis technology to remove impurities to obtain a solution A. The precipitate is added to a PBS solution and resuspended in a test tube, added to liquid nitrogen and repeatedly frozen and thawed 4-6 times, and then high-speed low-temperature centrifugation is performed using an ultrasonic disruptor to obtain a supernatant B, and then solution A and supernatant B are mixed to obtain a leukocyte extract, and the protein concentration is measured to ensure that the range is 0.7mg / ml-2.0mg / ml.
[0031] A freeze-drying protective agent is added to the leukocyte extract and mixed evenly so that the amount contained in each 100 ml of the total liquid is as follows: mannitol 0.05-4.0 g, trehalose 0.05-4.0 g, vitamin E 0.05-4.0 g, sucrose 0.05-4.0 g, ascorbic acid 0.1-4.0 g, polyethylene glycol 0.1-4.0 g, and arginine 0.1-0.4 g.
[0032] Finally, pre-cool at minus 80 degrees Celsius for 3 hours, pre-vacuum at minus 30 degrees Celsius, maintain for one hour and control the vacuum degree at 5-15Pa; sublimation drying time is 10 hours at minus 10 degrees Celsius while the vacuum degree remains unchanged; finally, analytical drying is carried out at 40 degrees Celsius for 1.5 hours to obtain freeze-dried white blood cell extract powder.
[0033] The leukocyte extract freeze-dried powder was subjected to a thermal stability test, and the test results are as follows: Lyophilized leukocyte extract powder was used for cell enzyme activity test: Resuscitated mouse fibroblasts were plated and subcultured into 6-well plates when the density reached 80-90%. Each well was inoculated with 1 X10 5Cells. After 24 hours of cell culture, the original culture medium was removed, and DMEM culture medium (containing 1% fetal bovine serum) containing animal leukocyte extracts at protein concentrations of 10μg / mL, 50μg / mL, 250ug / mL, and 500μg / mL was added to each group. 100pL of DMEM culture medium containing 1% fetal bovine serum was used as the control group. After the cells were cultured for another 12 hours, the culture medium was removed, and the mouse fibroblasts were collected by centrifugation using a cell scraper. The cooled cell lysis buffer was added for ultrasonic disruption. After the ultrasonic disruption was completed, the cells were centrifuged at 4°C and 10000Xg for 10 minutes, and the supernatant was collected. The superoxide dismutase and glutathione kits were used for detection, and the test results are as follows Figure 2 and Figure 3 As shown, the results show that the antioxidant enzyme activity of mouse fibroblasts can be effectively improved.
[0034] Lyophilized leukocyte extracts were subjected to photoaging testing for oxidative damage: According to relevant research, human skin is usually exposed to the outside. When exposed to ultraviolet rays for a long time, the skin will appear loose, pigmented, rough, and thickened. In severe cases, skin lesions will occur, which is medically called photoaging. Exposure to ultraviolet rays can cause damage to skin cells through inflammatory reactions and indirect oxidative stress, mainly causing peroxidation of polyunsaturated fatty acids (PUFA) in the skin and the formation of DNA adducts, such as 8-hydroxy-2'-deoxyguanosine (8-OHdG), which is a recognized marker of oxidative DNA damage. Autophagy is an intracellular cleaning and self-protection system that can maintain the homeostasis of skin structure. When exposed to ultraviolet rays, the level of autophagy in cells will increase, but autophagy can only play a role in delaying damage. In particular, critical ultraviolet irradiation will lead to the production of reactive oxygen species (ROS). The accumulation of ROS will cause harmful chemical reactions to cellular components (such as DNA, proteins and lipids), and will also consume superoxide dismutase (SOD), glutathione peroxidase (GSH-PX) and catalase (CAT). Malondialdehyde (MDA) is the final product of lipid peroxidation. The higher its content, the more serious the oxidative damage to the cells. ROS will react with unsaturated fatty acids in the cell membrane to produce MDA, destroying the antioxidant defense system, thus leading to oxidative stress. ROS will also activate the mitogen-activated protein kinase (MAPK) signaling pathway, thereby activating nuclear factor κB (NF-κB), and upregulating the expression of inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). The upregulation of inflammatory factors will aggravate the transcriptional expression of MMP-1. MMP-1 can degrade collagen, is the main cause of skin sagging, and is one of the markers of photoaging.
[0035] (1) The mice were randomly divided into 6 groups, with 6 mice in each group (half male and half female). The specific groups were: ① Normal group: hair removal + PBS application; ② Model group: hair removal + UV irradiation + PBS application; ③ Low concentration group: hair removal + UV irradiation + application; ④ 50μg / ml group: hair removal + UV + application; ⑤ 250μg / ml group: hair removal + UV irradiation + application; ⑥ 500μg / ml: hair removal + UV irradiation + application. Use an electric hair clipper to cut the hair on the back of the mouse, then use depilatory cream to remove fine hair, and finally use PBS and clean toilet paper to clean the depilatory cream and wipe it dry; (2) A UV irradiation device was constructed using three 40 W UVA lamps and one 40 W UVB lamp. The light source was 30 cm away from the animal's back. The mice were placed in a homemade cage with their back skin exposed and placed in the center of the UV irradiation device. For the first 5 days, the mice were exposed to UV irradiation for 10 min per day. From the 6th to the 10th day, they were exposed to UV irradiation for 20 min per day. From the 11th to the 40th day, they were exposed to UV irradiation for 30 min per day. (3) The mouse skin was photographed and observed every 10 days. At the end of the experimental period, the mice were killed and the back skin was taken for the next step of analysis. For specific results, please refer to Figure 4 .
[0036] The experimental results show that the animal leukocyte extract freeze-dried powder of the present application can have a good therapeutic effect on photoaging caused by oxidative damage, which indirectly verifies its antioxidant properties.
[0037] The above descriptions are only optional embodiments of the present invention, and are not intended to limit the patent scope of the present invention. All equivalent structural changes made using the contents of the present invention's specification and drawings, or directly / indirectly applied in other related technical fields, are included in the patent protection scope of the present invention.
Claims
1. A method for preparing a freeze-dried powder of animal leukocyte extract with antioxidant activity, characterized in that: The following steps are involved: S1: Take animal blood, add anticoagulant, then add PBS solution to dilute and mix well to obtain a primary mixed solution; S2: Add lymphocyte separation solution to the initial mixed solution, perform density gradient centrifugation to separate the layers, take the middle layer to obtain mononuclear cells, wash them, and then inoculate them in culture medium for cultivation.
2. S3: When the cell density in the culture medium reaches the set threshold, subculture is performed and fresh culture medium is replaced for cultivation; S4: The cultured cells are collected by centrifugation to obtain a supernatant and a precipitate, and the supernatant is treated by an ultrafiltration concentration device to obtain a solution A; the precipitate is added with a PBS solution for resuspending, and after low-temperature centrifugation, a supernatant B is obtained, and the solution A and the supernatant B are mixed to obtain a leukocyte extract; S5: adding a lyophilization protective agent to the leukocyte extract, pre-cooling after mixing evenly, sublimation drying after pre-vacuuming, and finally analytical drying to obtain the animal leukocyte extract antioxidant active lyophilized powder.
3. The preparation method according to claim 1, characterized in that: In step S1, the selected animal blood is peripheral blood; the anticoagulant is one of heparin or sodium citrate.
4. The preparation method according to claim 1, characterized in that: In step S2, the monocytes are washed several times with PBS solution and then inoculated in DMEM medium for culture at a temperature of 37 degrees Celsius and a carbon dioxide concentration of 5%; wherein the DMEM medium contains 5% FBS, 150U interleukin and 5 μg / ml fibronectin.
5. The preparation method according to claim 1, characterized in that: In step S3, when the cell density reaches 80-90%, the cells are subcultured and the culture medium is replaced with new medium for 10 days.
6. The preparation method according to claim 1, characterized in that: In step S4, the supernatant is concentrated by ultrafiltration using 0.22um and 0.45um filter membranes to remove impurities to obtain solution A; the precipitate is resuspended with PBS solution, added to liquid nitrogen for repeated freezing and thawing, centrifuged at high speed and low temperature using an ultrasonic disruptor, and then separated to obtain supernatant B.
7. The preparation method according to claim 5, characterized in that: In the process of obtaining supernatant B, when using an ultrasonic disruptor, the conditions adopted are ultrasonication for 1-3 seconds in an ice bath, with an interval of 5-8 seconds, lasting for 10 minutes, and 2-3 cycles.
8. The preparation method according to claim 1, wherein in step S5, the added lyoprotectant is a mixture of one or more of trehalose, arginine, dextran, sucrose, lactose, mannitol, arginine, and D-fructose, and the added amount is 6%-15% of the mass of the leukocyte extract solution, and polyethylene glycol is also added.
Citation Information
Patent Citations
Leukocyte extract and preparation method and application thereof
CN104622777A
Anti-wrinkle essence powder and preparation method thereof
CN111714439A
Moisturizing skin-tenderizing essence powder and preparation method thereof
CN111714440A
Antioxidant composition, and preparation method thereof and skin care product
CN113750031A
Preparation method of leukocyte extract for cosmetics and freeze-dried powder of leukocyte extract
CN114522135A
